PL394618A1 - Przeciwnowotworowe bialko fuzyjne - Google Patents

Przeciwnowotworowe bialko fuzyjne

Info

Publication number
PL394618A1
PL394618A1 PL394618A PL39461811A PL394618A1 PL 394618 A1 PL394618 A1 PL 394618A1 PL 394618 A PL394618 A PL 394618A PL 39461811 A PL39461811 A PL 39461811A PL 394618 A1 PL394618 A1 PL 394618A1
Authority
PL
Poland
Prior art keywords
fusion protein
domain
sequence
terminus
functional fragment
Prior art date
Application number
PL394618A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Piotr Kamil Rózga
Urszula Marta Szawłowska
Krzysztof Kazimierz Lemke
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL394618A priority Critical patent/PL394618A1/pl
Priority to NZ617353A priority patent/NZ617353B2/en
Priority to AU2012244654A priority patent/AU2012244654A1/en
Priority to MX2013012242A priority patent/MX2013012242A/es
Priority to CA2832152A priority patent/CA2832152A1/en
Priority to JP2014505636A priority patent/JP2014513943A/ja
Priority to CN201280019018.5A priority patent/CN103562220A/zh
Priority to BR112013025975A priority patent/BR112013025975A2/pt
Priority to US14/008,234 priority patent/US20140031283A1/en
Priority to SG2013070826A priority patent/SG193925A1/en
Priority to PCT/EP2012/057219 priority patent/WO2012143477A2/en
Priority to EA201391546A priority patent/EA201391546A1/ru
Priority to EP12715691.7A priority patent/EP2699592A2/en
Priority to KR1020137029312A priority patent/KR20140019828A/ko
Publication of PL394618A1 publication Critical patent/PL394618A1/pl
Priority to ZA2013/08597A priority patent/ZA201308597B/en
Priority to IL228731A priority patent/IL228731A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL394618A 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne PL394618A1 (pl)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne
BR112013025975A BR112013025975A2 (pt) 2011-04-19 2012-04-19 proteína de fusão anticancerígena
US14/008,234 US20140031283A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
MX2013012242A MX2013012242A (es) 2011-04-19 2012-04-19 Proteina de fusion anticancerigena.
CA2832152A CA2832152A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
JP2014505636A JP2014513943A (ja) 2011-04-19 2012-04-19 抗がん融合タンパク質
CN201280019018.5A CN103562220A (zh) 2011-04-19 2012-04-19 抗癌融合蛋白
NZ617353A NZ617353B2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
AU2012244654A AU2012244654A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
SG2013070826A SG193925A1 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
PCT/EP2012/057219 WO2012143477A2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
EA201391546A EA201391546A1 (ru) 2011-04-19 2012-04-19 Противораковый слитый белок
EP12715691.7A EP2699592A2 (en) 2011-04-19 2012-04-19 Anticancer fusion protein
KR1020137029312A KR20140019828A (ko) 2011-04-19 2012-04-19 항암 융합 단백질
ZA2013/08597A ZA201308597B (en) 2011-04-19 2013-11-15 Anticancer fusion protein
IL228731A IL228731A0 (en) 2011-04-19 2013-11-21 anticancer fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne

Publications (1)

Publication Number Publication Date
PL394618A1 true PL394618A1 (pl) 2012-10-22

Family

ID=45990644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL394618A PL394618A1 (pl) 2011-04-19 2011-04-19 Przeciwnowotworowe bialko fuzyjne

Country Status (15)

Country Link
US (1) US20140031283A1 (pl)
EP (1) EP2699592A2 (pl)
JP (1) JP2014513943A (pl)
KR (1) KR20140019828A (pl)
CN (1) CN103562220A (pl)
AU (1) AU2012244654A1 (pl)
BR (1) BR112013025975A2 (pl)
CA (1) CA2832152A1 (pl)
EA (1) EA201391546A1 (pl)
IL (1) IL228731A0 (pl)
MX (1) MX2013012242A (pl)
PL (1) PL394618A1 (pl)
SG (1) SG193925A1 (pl)
WO (1) WO2012143477A2 (pl)
ZA (1) ZA201308597B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
ES2805360T3 (es) 2013-03-15 2021-02-11 Tdw Group Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
EP3266796B1 (en) * 2015-03-02 2018-12-19 Chengdu Huachuang Biotechnology Co., Ltd Trail membrane-penetrating peptide-like mutant mur5, preparation method therefor, and application thereof
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
EP3609527A4 (en) * 2017-03-29 2021-01-20 TDW Group PROTEIN CONJUGATES
WO2024159087A1 (en) * 2023-01-26 2024-08-02 Dana-Farber Cancer Institute, Inc. Developing a car-engager platform to enhance the functionality and/or persistence of car t cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
IL154696A (en) * 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
JP4688678B2 (ja) 2003-11-03 2011-05-25 北京沙東生物技術有限公司 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
CN1256347C (zh) 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
WO2006074451A2 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2190861A4 (en) * 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Also Published As

Publication number Publication date
US20140031283A1 (en) 2014-01-30
EP2699592A2 (en) 2014-02-26
EA201391546A1 (ru) 2014-02-28
MX2013012242A (es) 2014-01-23
CA2832152A1 (en) 2012-10-26
WO2012143477A2 (en) 2012-10-26
BR112013025975A2 (pt) 2016-11-29
CN103562220A (zh) 2014-02-05
JP2014513943A (ja) 2014-06-19
NZ617353A (en) 2015-01-30
WO2012143477A3 (en) 2013-03-14
AU2012244654A1 (en) 2013-11-21
SG193925A1 (en) 2013-11-29
KR20140019828A (ko) 2014-02-17
ZA201308597B (en) 2014-12-23
IL228731A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
PH12014501083A1 (en) Anticancer fusion protein
MX2013007872A (es) Proteina de fusion anticancer.
MX2013006213A (es) Proteina de funsion anticancer.
MX352796B (es) Proteina de fusion anticancerigena.
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
MX2015004060A (es) 3-epimerasa.
MY167232A (en) Polypeptides binding to human complement c5
WO2016004906A3 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
WO2014057436A3 (en) Anticancer conjugate
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
GB201019467D0 (en) Therapeutic agent
NZ795140A (en) Polypeptide variants and uses thereof
WO2011150897A3 (es) Método para la terapia del cáncer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)